TABLE 2.
Table lists the top terms of GO biological processes (BPs) and immune system processes (ISPs) enriched with 1,227 overlapped DEGs in response to Lena strain infection at 8–13 dpi
| GO term | % associated genes/term | No. of genes | Associated genes found | |
|---|---|---|---|---|
| T cell signaling pathways | ||||
| α/β T cell differentiation | 25.23 | 37.00 | AGER, 8CL118, CCR2, CD274, CD28, CD3E, CD55, CRTAM, EBl3, EOMES, GATA3, GPR18, GPR183, HLX, IFNG, IL18R1, IRF4, ITK, LY9, NFK81Z, NLRP3, PRDM1, PTPN22, RORA, RSAD2, RUNX3, SAT81, SFTPA1, SOCS1, T8 × 21, TCF7, TOX, ZAP70, ZBT816, ZC3H12A, ZFPM1, ZNF683 | |
| Regulation of α/β T cell activation | 24.00 | 24.00 | AGER, CCR2, CD274, CD28, CD3E, CD55, CRTAM, E8I3, GATA3, HLX, IFNG, IRF4, LILR81, NFK8IZ, NLRP3, PRDM1, PTPN22, RUNX3, SOCS1, T8 × 21, ZAP70, Z8T816, ZC3H12A, ZNF683 | |
| T cell selection | 32.69 | 17.00 | 8CL 118, CARD11, CCR7, CD1D, CD28, CD3D, CD3E, CD3G, CD4, GATA3, IRF4, LY9, T8 × 21, THEMIS, TOX, ZAP70, ZFPM1 | |
| T cell co-stimulation | 23.08 | 15.00 | CARD11, CCR7, CD274, CD28, CD3E, CD40LG, CDS, CTLA4, EPH86, GRAP2, ICOS, KLRK1, LCK, MAP3K8, PDCD1 | |
| Regulation of T cell receptor signaling pathway | 28.26 | 15,00 | CARD11, CCR7, CD226, G8P1, GCSAM, LCK, PRKCH, PRKD2, PTPN22, PVRIG, SH2D1A, SLA2, THY1, TRAT1, U8ASH3A | |
| CD8+ α/β T cell activation | 35.71 | 10.00 | CD274, CRTAM, EOMES, GPR18, LILR81, PTPN22, RUNX3, SAT81, SOCS1, TOX | |
| CD4+ CD25+ α/β T cell cytokine production | 34.78 | 8.00 | CD55, GATA3, IL18R1, IL18, NLRP3, RSAD2, T8 × 21, TINAGL1 | |
| Regulation of T-helper type immune response | 21.43 | 6.00 | CCR2, HAVCR2, HLX, IL 18R1, IL18, IL1 RL1 | |
| NK T cell differentiation | 50.00 | 6.00 | ITK, PRDM1, SFTPA1, TOX, Z8T816, ZNF683 | |
| Lymphocyte chemotaxis | 24.24 | 30.00 | ADAM8, CCL11, CCL2, CCL20, CCL22, CCL3L 1, CCL4, CCL5, CCR2, CCR5, CCR7, CMKLR1, CXCL 10, CXCL 13, CXCL 14, CXCL2, CXCR3, CXCR6, EDN1, GCSAM, GPR75, GPR183, ITG87, KLRK1, PP8P, RIPOR2, S1PR1, STK39, ZAP70, XCR1 | |
| Regulation of IFN-y production | 24.11 | 27.00 | CCR2, CCR7, CD2, CD226, CD274, CD3E, CD96, CRTAM, E8I3, GATA3, HAVCR2, IL 10, IL 12R82, IL 18R1, IL18, IL1RL 1, INH8A, ISG15, KLRK1, LILR81, PDE48, PDE40, PTPN22, RASGRP1, TNF, ZC3H12A, ZFPM1 | |
| Chemokine-mediated signaling pathway | 23.33 | 25.00 | ADAM8, CCL 11, CCL2, CCL20, CCL22, CCL3L 1, CCL4, CCL5, CCR2, CCR5, CCR7, CMKLR1, CXCL 10, CXCL 13, CXCL 14, CXCL2, CXCR3, CXCR6, EDN1, GPR75, GPR183, KLRK1, PP8P, STK39, XCR1 | |
| Cytokine receptor activity | 22.00 | 22.00 | CCR2, CCR5, CCR7, CD4, CMKLR1, CRLF2, CXCR3, CXCR6, E8I3, GPR75, IL12R82, IL15RA, IL18R1, IL18RAP, IL1R2, IL1RAP, IL1RL1, IL21R, IL2RA, IL2R8, IL7R, XCR1 | |
| Natural killer cell mediated immunity | 20.00 | 18.00 | CD1A, CD1 D, CD226, CD96, CRTAM, GZM8, HAVCR2, KLRK1, F2RL1, ITGAM, LAG3, LILR81, RA827A, RASGRP1, SERPIN89, SH2D1A, SLAMF7, TINAGL 1 | |
| Regulation of IL-2 production | 27.87 | 17.00 | CARD11, CCR2, CD28, CD3E, CD4, GATA3, G8P1, HAVCR2, IL18, IRF4, LAG3, PDE48, PDE4O, PRKD2, SFTPD, T8 × 21, TNFAIP3, MEFV, TIGIT | |
| Regulation of vitamin D biosynthetic process | 44.00 | 12.00 | ADAM8, CST7, IFNG, IL 10, IL 18, MMP8, NUPR1, SPHK1, SNAI1, TNF, TIMP1, TIMP3 | |
| Regulation of IL-12 production | 20.00 | 12.00 | ACP5, AGER, CCR7, CD40LG, CMKLR1, 1001, IFNG, IL 10, LILR81, LT8, | |
| Negative regulation of IFN-I production | 23.40 | 11.00 | ACOD1, DHX58, HAVCR2, HERC5, IL 10, ISG15, LILR81, NLRC3, RNF125, TNFAIP3, U8E2L6 | |
| Negative regulation of IFN-γ production | 22.50 | 9.00 | CD274, CD96, GATA3, HAVCR2, IL 10, IL 1RL 1, INH8A, LILR81, ZC3H12A | |
| Positive regulation of leukocyte apoptotic process | 23.53 | 8.00 | ADAM8, CCL5, CD27, CD274, IDO1, IL10, NR4A3, PDCD1 | |
| Regulation of lipopolysaccharide-mediated signaling pathway | 20.00 | 8.00 | ACOD1, CD180, CD55, F2RL 1, LTF, PTPN22, PRKCA, TNFAIP3 | |
| Regulation of IL-4 production | 25.81 | 8.00 | CD28, CD3E, CD40LG, GATA3, HAVCR2, IRF4, NLRP3, ZFPM1 | |
| Regulation of tolerance induction | 35.00 | 7.00 | CD274, CD3E, HAVCR2, IDO1, IL2RA, MARCHF7, PDCD1 | |
| Positive regulation of IL-5 production | 46.15 | 6.00 | CRLF2, GATA3, IL 1RAP, IL 1RL 1, NLRP3, PDE4O | |
| Regulation of chronic inflammatory response | 60.00 | 6.00 | ADORA28, CCL5, IDO1, IL 10, TNF, TNFAIP3 | |
| Negative regulation of lymphocyte migration | 28.67 | 4.00 | CCL2, GCSAM, KLRK1, RIPOR2 | |
| lnterleukin-1 receptor activity | 57.14 | 4.00 | IL18R1, IL 1 R2, IL 1 RAP, IL 1 RL 1 | |
| Negative regulation of IFN-α production | 42.86 | 3.00 | HAVCR2, IL 10, NLRC3 | |
| Positive regulation of apoptotic cell clearance | 33.33 | 3.00 | C3, C4A, CCL2 | |
| Epithelial cell morphogenesis | 21.95 | 9.00 | 8CL 118, CCDC88C, CLDN3, COL 18A1, FAT1, FLN8, HEG1, HRH2, PECAM1 | |
| Other pathways | ||||
| Regulation of vascular endothelial growth factor production | 21.21 | 7.00 | ADORA28, C3, CCR2, HPSE, IL 18, RORA, SULF2 | |
| Regulation of extracellular matrix disassembly | 21.05 | 4.00 | CARMIL2, ETS1, FSCN1, PDPN | |
| G protein-coupled purinergic nucleotide receptor activity | 26.67 | 4.00 | P2RY10, P2RY13, P2RY6, P2RY8 | |
| lnositol phosphate dephosphorylation | 25.00 | 4.00 | INPP1, INPP48, INPP58, SYNJ2 |